Cargando…
Liposome delivery systems for the treatment of Alzheimer’s disease
Alzheimer’s disease (AD) will affect around 115 million people worldwide by the year 2050. It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and tau) in the senile plaques and neurofibrillary tangles found in the brain. Currently available drugs for AD only tempo...
Autores principales: | Ross, Callum, Taylor, Mark, Fullwood, Nigel, Allsop, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296687/ https://www.ncbi.nlm.nih.gov/pubmed/30587974 http://dx.doi.org/10.2147/IJN.S183117 |
Ejemplares similares
-
Liposome based drug delivery as a potential treatment option for Alzheimer's disease
por: Hernandez, Carely, et al.
Publicado: (2021) -
Liposomes as Adjuvants and Vaccine Delivery Systems
por: Tretiakova, D. S., et al.
Publicado: (2022) -
Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease)
por: Spuch, Carlos, et al.
Publicado: (2011) -
Liposomal Drug Delivery Systems and Anticancer Drugs
por: Olusanya, Temidayo O. B., et al.
Publicado: (2018) -
Building Blocks to Design Liposomal Delivery Systems
por: Juszkiewicz, Katarzyna, et al.
Publicado: (2020)